Contact Us
Contact Us
Contact Us


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

19/06/2020Updated Bisantrene Phase II Data PresentationDownload
17/06/2020Race Oncology Phase II Bisantrene AML trial webinarDownload
16/06/2020Impressive 40% response in Phase II Bisantrene AML TrialDownload
16/06/2020Extension of time to repay loan through share buy-backDownload
12/06/2020Trading HaltDownload
01/06/2020Phillip Lynch appointed Director of RaceDownload
01/06/2020Initial Director's Interest NoticeDownload
28/05/2020Extension of time to repay loanDownload
21/05/2020Final Director's Interest NoticeDownload
20/05/2020Managing Director ResignationDownload
1  2  3  4  5  6  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2020 Race Oncology. Website By Multiplier